Gray-black macules in a patient with melanoma

Affiliations

¹ Department of Internal Medicine, Kettering Health Network, Dayton, Ohio.
² Department of Pathology, University of Cincinnati Medical Center, Cincinnati, Ohio.
³ Department of Hematology-Oncology, University of Cincinnati Health, Cincinnati, Ohio.

Kristin Petit et al. JAAD Case Rep. 2022.

. 2022 Aug 23:28:113-115.

doi: 10.1016/j.jdcr.2022.08.021. eCollection 2022 Oct.

¹ Department of Internal Medicine, Kettering Health Network, Dayton, Ohio.
² Department of Pathology, University of Cincinnati Medical Center, Cincinnati, Ohio.
³ Department of Hematology-Oncology, University of Cincinnati Health, Cincinnati, Ohio.

No abstract available

Keywords: cutaneous oncology; immunotherapy; malignant melanoma; melanoma; melanophage; metastatic melanoma; pigmented lesion; tumoral melanosis.

Conflict of interest statement

None disclosed.

1. Bari O., Cohen P.R. Tumoral melanosis associated with pembrolizumab-treated metastatic melanoma. Cureus. 2017;9 doi: 10.7759/cureus.1026. - DOI - PMC - PubMed
1. Relvas M., Alves F., Mariano A., Cardoso J., Coutinho I. Tumoral melanosis after immunotherapy with pembrolizumab—a response sign mimicking melanoma. Dermatol Online J. 2020;26(10) doi: 10.5070/d32610050460. - DOI - PubMed
1. Grohs R.L., Mesbah Ardakani N. Melanoma manifesting as tumoral melanosis; now you see it, now you don't. Am J Dermatopathol. 2018;40(6):462–465. doi: 10.1097/DAD.0000000000000848. - DOI - PubMed
1. Laino A., Shepherd B., Atkinson V., Fu H., Soyer H.P., Schaider H. Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma. JAAD Case Rep. 2018;4(9):921–923. doi: 10.1016/j.jdcr.2018.06.024. - DOI - PMC - PubMed
1. Demirdağ H.G., Akay B.N., Kırmızı A., Heper A.O. Tumoral melanosis arising on a mycosis fungoides plaque. Balkan Med J. 2018;35(6):447–448. doi: 10.4274/balkanmedj.2018.0936. - DOI - PMC - PubMed